These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 17587845)

  • 21. Cyclical Inguinal Keratoderma: A New Clinical Entity or a Variant of Pityriasis Rubra Pilaris?
    Kumarasinghe SP; Kim J; Yu L; Papadimitriou J
    Australas J Dermatol; 2016 Aug; 57(3):243-4. PubMed ID: 27469485
    [No Abstract]   [Full Text] [Related]  

  • 22. Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis.
    Caporali R; Cavagna L; Bellosta M; Bogliolo L; Montecucco C
    Clin Rheumatol; 2004 Feb; 23(1):63-5. PubMed ID: 14749988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photoaggravated pityriasis rubra pilaris.
    Evangelou G; Murdoch SR; Palamaras I; Rhodes LE
    Photodermatol Photoimmunol Photomed; 2005 Oct; 21(5):272-4. PubMed ID: 16149942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.
    Katharina M; Sylvia S; Matthias B; Ulrich M; Martin L
    Pediatr Dermatol; 2022 Jul; 39(4):659-661. PubMed ID: 35859269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
    Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
    J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical treatment of pityriasis rubra pilaris with calcipotriol.
    Van de Kerkhof PC; Steijlen PM
    Br J Dermatol; 1994 May; 130(5):675-8. PubMed ID: 7515639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of pityriasis rubra pilaris with ustekinumab.
    Wohlrab J; Kreft B
    Br J Dermatol; 2010 Sep; 163(3):655-6. PubMed ID: 20491761
    [No Abstract]   [Full Text] [Related]  

  • 28. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
    Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
    Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
    Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
    J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab.
    Ruzzetti M; Saraceno R; Carboni I; Papoutsaki M; Chimenti S
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):117-8. PubMed ID: 18181990
    [No Abstract]   [Full Text] [Related]  

  • 32. Pityriasis rubra pilaris: a review of diagnosis and treatment.
    Cohen PR; Prystowsky JH
    J Am Acad Dermatol; 1989 May; 20(5 Pt 1):801-7. PubMed ID: 2654219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.
    Cole D; Mohammad T; Lim H
    Br J Dermatol; 2019 Dec; 181(6):1331-1332. PubMed ID: 31260082
    [No Abstract]   [Full Text] [Related]  

  • 35. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.
    Petrof G; Almaani N; Archer CB; Griffiths WA; Smith CH
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e131-5. PubMed ID: 22324561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Pityriasis Rubra Pilaris With Guselkumab.
    Pilz AC; Seiringer P; Biedermann T; Eyerich K
    JAMA Dermatol; 2019 Dec; 155(12):1424-1426. PubMed ID: 31577328
    [No Abstract]   [Full Text] [Related]  

  • 37. Pityriasis rubra pilaris responding rapidly to adalimumab.
    Walling HW; Swick BL
    Arch Dermatol; 2009 Jan; 145(1):99-101. PubMed ID: 19153364
    [No Abstract]   [Full Text] [Related]  

  • 38. Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor α-blocking agents and acitretin.
    López-Ferrer A; Dalmau J; Fernández-Figueras MT; Puig L
    Cutis; 2014 Mar; 93(3):E6-7. PubMed ID: 24738108
    [No Abstract]   [Full Text] [Related]  

  • 39. Pityriasis rubra pilaris successfully treated with infliximab.
    Ruiz-Genao DP; Lopez-Estebaranz JL; Naz-Villalba E; Gamo-Villegas R; Calzado-Villarreal L; Pinedo-Moraleda F
    Acta Derm Venereol; 2007; 87(6):552-3. PubMed ID: 17989902
    [No Abstract]   [Full Text] [Related]  

  • 40. Risankizumab for pityriasis rubra pilaris.
    Brocco E; Laffitte E
    Clin Exp Dermatol; 2021 Oct; 46(7):1322-1324. PubMed ID: 33914925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.